MID REGIONAL PRO-ADRENOMEDULLIN (MR-PROADM) IS SUPERIOR TO BNP (B-TYPE NATRIURETIC PEPTIDE) IN PREDICTING MORTALITY IN STABLE OUTPATIENTS WITH STAGE A HEART FAILURE FOLLOWED FOR 6 YEARS  by Taub, Pam et al.
E195
JACC April 5, 2011
Volume 57, Issue 17
  CARDIAC FUNCTION AND HEART FAILURE 
MID REGIONAL PRO-ADRENOMEDULLIN (MR-PROADM) IS SUPERIOR TO BNP (B-TYPE NATRIURETIC 
PEPTIDE) IN PREDICTING MORTALITY IN STABLE OUTPATIENTS WITH STAGE A HEART FAILURE 
FOLLOWED FOR 6 YEARS
ACC Oral Contributions
Ernest N. Morial Convention Center, Room 243
Monday, April 04, 2011, 3:00 p.m.-3:15 p.m.
Session Title: Cardiomyopathy: Bench to Bedside
Abstract Category: 22. Cardiomyopathies/Myocarditis/Pericardial Disease
Presentation Number: 914-7
Authors: Pam Taub, Yang Xue, Navaid Iqbal, Arrash Fard, Paul Clopton, Alan Maisel, University of California San Diego, San Diego, CA, VA San Diego 
Healthcare System, San Diego, CA
Background:  Adrenomedullin is a vasodilatory peptide elevated in many pathological disease states. In the BACH trial of 1641 patients, MR-
proADM (a stable prohormone reflective of adrenomedullin levels) was predictive of mortality at 90 days in patients with acute heart failure. We 
examined the prognostic value of MR-proADM in stable outpatients with heart failure (HF).
Methods:  We obtained MR-proADM and BNP levels in 726 outpatients referred for routine echocardiography at the San Diego VA Hospital. These 
patients were followed for 6 years. Primary outcome was all cause mortality.
Results:  There were 198 stage A patients, 338 stage B patients and 200 stage C/D patients with average age of 68 ±12 and195 deaths. Optimal 
MR-proADM cut point derived from ROC analysis was 0.72 nmol/l. MR-proADM was predictive of mortality in all patients (p<0.001) and in each 
stages of HF (Figure 1) and more predictive than BNP and echocardiographic indices of structural heart disease and systolic function. In stage A HF, 
MR-proADM was predictive of mortality (p=.002 HR 3.2) while BNP was not (p=0.111).
Conclusions:  In this first study to assess the prognostic value of MR-proADM in stable outpatients with a long follow up period of 6 years, MR-
proADM was a potent predictor of all cause mortality. MR-proADM maybe particularly useful for risk stratification of Stage A HF in which there are 
currently no reliable methods of predicting outcomes. A biomarker guided treatment strategy in Stage A HF may help prevent disease progression. 
